No Data
Sector Update: Health Care Stocks Slide Late Afternoon
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Express News | RBC Capital Reiterates Sector Perform on Bluebird Bio, Maintains $4 Price Target
Bluebird Bio Downgraded by Bank of America, Shares Tumble | NASDAQ:BLUE
Bluebird Bio Extends Selloff as BofA and J.P. Morgan Cuts After Q3 Results
Bluebird Bio Is Maintained at Overweight by Barclays